In Brief: U.S. Surgical
This article was originally published in The Gray Sheet
Executive Summary
U.S. Surgical: Maintains in Oct. 14 comments to FDA that it has legal authority to seek rejection of Sofamor Danek's premarket approval application for its Novus LC threaded interbody fusion system. USSC petitioned FDA in July to turn down the Novus PMA because it lacks two-year follow-up data, and Sofamor Danek responded by claiming that USSC could not participate in the review process and that FDA did not have a two-year rule ("The Gray Sheet" Aug. 11, I&W-3). FDA has "created a de facto policy requiring such data" and has "consistently enforced this policy over the years with respect to orthopedic implantable devices," USSC maintains...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.